Floatz logo

Metformin

Ovarian Undifferentiated Adenocarcinoma

University of ChicagoSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Ovarian Undifferentiated Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
National Cancer Institute (NCI)
Phase 3BBB
Inno-206
National Cancer Institute (NCI)
Phase 3BB
Cediranib
National Cancer Institute (NCI)
Phase 3BB
Olaparib
National Cancer Institute (NCI)
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Gynecologic Oncology Group
Phase 3BB

View all 32 →

Same molecule, other indications

Metformin is also rated in:

Metabolism and Nutrition DisorderDormant
A
Indicative ·
82 / 100
View asset →
prediabetes syndromeDormant
A
Indicative ·
81 / 100
View asset →
gestational diabetesDormant
A
Indicative ·
81 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →